Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI Ronald OuwerkerkMichael A. JacobsPaul A. Bottomley Preclinical Study/Clinical Trial/Epidemiology/Invited Comentary 27 January 2007 Pages: 151 - 160
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors Alvin EisnerMaureen D. ToomeyJohn T. Vetto Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary Open access 27 January 2007 Pages: 161 - 170
Breast duct anatomy in the human nipple: three-dimensional patterns and clinical implications Jennifer E. RusbyElena F. BrachtelBarbara L. Smith Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary 13 January 2007 Pages: 171 - 179
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Edurne ArriolaSocorro Maria Rodriguez-PinillaJorge S. Reis-Filho Preclinical Study 27 January 2007 Pages: 181 - 189
A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer Louise M. RasmussenNurulain T. ZaveriAnne E. Lykkesfeldt Preclinical Study 01 February 2007 Pages: 191 - 203
Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk Annika VaclavicekJusto Lorenzo BermejoAsta Försti Preclinical Study 01 February 2007 Pages: 205 - 213
A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models Hiroyuki IshidaTaisuke NakataShiro Akinaga Preclinical Type 01 February 2007 Pages: 215 - 227
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial Gershon Y. LockerRobert Manselon behalf of the ATAC Trialists’ Group Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary 24 January 2007 Pages: 229 - 238
Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients Sven BeckerErich SolomayerTanja Fehm Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary 27 January 2007 Pages: 239 - 243
Trends in breast cancer treatment in Korea and impact of compliance with consensus recommendations on survival Young Ho YunSang Min ParkEun Sook Lee Clinical Trial 15 February 2007 Pages: 245 - 253
Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling E. BeristainC. Martínez-BouzasM. I. Tejada Epidemiology 30 January 2007 Pages: 255 - 262
Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis Debora MacisPatrick MaisonneuveAndrea Decensi Epidemiology 27 January 2007 Pages: 263 - 271
Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women Jun WangRussell HiguchiBrian Rhees Epidemiology 01 February 2007 Pages: 273 - 280
Alcohol metabolism, alcohol intake, and breast cancer risk: a sister-set analysis using the Breast Cancer Family Registry Mary Beth TerryJulia A. KnightRegina M. Santella Epidemiology 01 February 2007 Pages: 281 - 288
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families Amelia BuffoneCarlo CapalboGiuseppe Giannini Epidemiology 28 February 2007 Pages: 289 - 296
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population Dewajani PurnomosariGerard PalsPaul J. van Diest Original Paper Open access 15 February 2007 Pages: 297 - 304